Sen-Jam Pharmaceutical (Equity)

Funding Details
Awarder
StartEngine
Date Award
June 13, 2024
Vertical
Pharmaceuticals
Funding URL
View Funding Page
Valuation
$69,980,000

Company Info
Founding Year
Not provided
Traction
Sen-Jam Pharmaceutical has enrolled patients in a Phase 2 Clinical Trial for a covid oral therapeutic in collaboration with Duke University. They are also preparing for a Phase 2 clinical trial for the prevention of alcohol’s toxic effects.
Organizations Involved
Duke University
Founders
James Iversen, Jacqueline M. Iversen, Neal Zahn
Company Description
Sen-Jam Pharmaceutical is developing a line of anti-inflammatory drugs designed to provide a much-needed update to a multi-billion dollar market that has seen little innovation in the past 30 years. They are focusing on harnessing the body’s immune system at the beginning of the inflammatory cascade to prevent acute inflammation, slow the progression of chronic illnesses, and improve health span.
Market
Healthcare
Location
Lloyd Harbor, NY, US
Coinvestors
StartEngine Capital, LLC

Links
Back to Home Back to Pharmaceuticals Deals View Funding Announcement